Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
High-dose vitamin D won't save dialysis patients, major trial finds. The large SIMPLIFIED trial found that giving dialysis patients high-dose vitamin D3 (cholecalciferol) every two weeks did not improve survival or reduce cardiovascular events, infections, or fractures compared to standard care. Intriguing signals emerged in male and non-white patients, but researchers say these findings are hypothesis-generating only.
Vitamin D deficiency is nearly universal in dialysis patients and has long been linked to higher risks of death, heart disease, and infection — making supplementation seem like an obvious fix. But the SIMPLIFIED trial, one of the largest dialysis studies ever conducted, found no survival benefit from high-dose supplementation.
Across 3,866 dialysis patients at 55 UK centers, those randomized to 60,000 IU of cholecalciferol every two weeks showed no significant improvement in survival or any secondary outcomes — including cardiovascular events, infections, fractures, or cancer — compared to standard care over up to 7.5 years of follow-up. Researchers say the findings do not support routine, population-wide high-dose vitamin D supplementation in dialysis patients.
By the Numbers:
Why it matters: Dialysis patients face devastatingly poor outcomes — half don't survive 5 years. KDIGO guidelines already acknowledge the low evidence base for vitamin D replacement in this population, and SIMPLIFIED now gives clinicians a clearer answer: high-dose cholecalciferol isn't the solution. The subgroup signals in non-white and male patients, however, may warrant targeted future trials.
